閉経後ホルモン受容体陽性進行乳がんにおけるエベロリムス

Baselgaらがこの問題を研究した。

www.synapsesocial.com/papers/69dff5e12833447a7e2556a4 — DOI: https://doi.org/10.1056/nejmoa1109653

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Toxicity and response criteria of the Eastern Cooperative Oncology Group· 1982 · 11,560 citations
2. Phase 3 trial of everolimus for metastatic renal cell carcinoma· 2010 · 1,142 citations
3. Discrete sequential boundaries for clinical trials· 1983 · 1,739 citations
4. Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer· 2006 · 106 citations
5. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer· 2010 · 631 citations